Article
Sanofi to Acquire Shantha for $784 Million
Author(s):
French drug manufacturer Sanofi Aventis will purchase the Indian vaccine company Shantha Biotechnics for $784 million.
French drug manufacturer Sanofi Aventis will purchase the Indian vaccine company Shantha Biotechnics for $784 million. This acquisition will give Sanofi a platform in India as well as access to a pipeline of new products.
Per the agreement, Sanofi's vaccine division Sanofi-Pasteur will acquire ShanH, French subsidiary of Merieux Alliance, which holds a majority stake in Hyderabad-based Shantha.
Sanofi Pasteur, Sanofi’s vaccine unit, will support Shantha’s development. Varaprasad Reddy, who founded Shantha in 1993, will continue leading the company as managing director.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
